Appendix F · Hormone Reference Table
How to use this appendix
There are roughly fifty hormones in this book, and students routinely try to learn them as fifty independent facts. That approach fails, and it fails predictably: fifty unlinked items exceed what anyone can hold, and the exam does not ask you to recite them anyway. It asks you what happens to a variable when a gland fails.
Learn hormones on three axes instead. Each one collapses a large amount of memorization into a small amount of reasoning.
1 · Chemical class predicts the physical behavior of the molecule. A hormone is either water-soluble (peptides, proteins, glycoproteins, and the catecholamines) or lipid-soluble (steroids and thyroid hormone). That single fact predicts four others: how it travels in plasma, how long it survives there, where its receptor sits, and how fast it acts (§16.2). Water-soluble hormones dissolve free in plasma, are cleared in seconds to minutes, bind surface receptors, and act through second messengers within seconds. Lipid-soluble hormones ride on carrier proteins, persist for hours to days, bind intracellular receptors, and act by changing gene transcription over hours. If you know the class, you have already answered half the questions that can be asked.
2 · The axis tells you where a lesion can hide. Most of the classic endocrine hormones sit in a three-tier chain: hypothalamus releases a trophic factor into the portal blood, anterior pituitary releases a tropic hormone into the systemic blood, target gland releases the effector hormone, and the effector hormone feeds back on both tiers above it. Once you can draw that chain, the diagnostic logic in §F.5 follows mechanically — and it is the same logic for the thyroid, the adrenal cortex, and the gonads.
3 · The defended variable tells you the point of the whole thing. Every hormone exists to hold some variable inside a range. Glucose. Plasma calcium. Extracellular fluid volume. Plasma osmolality. Core metabolic rate. Plasma sodium. Oxygen-carrying capacity. When you meet a hormone you cannot recall, ask what it is defending; the actions usually fall out of the answer. Aldosterone defends extracellular fluid volume, therefore it retains sodium, therefore it retains water, therefore it raises blood pressure, therefore it excretes potassium and hydrogen ion in the exchange. That is one fact expanded into five.
Using the master table well
Do not read §F.2 straight through. It is a lookup table, not a chapter. Use it three ways: cover the "Principal actions" column and generate them from the source and class; cover the "Stimulus" column and predict what would logically trigger release given the defended variable; and after finishing a chapter, return here and read only the rows that chapter introduced, checking them against what you can already say without looking.
F.1 Chemical class at a glance
| Class | Examples | Transport in plasma | Half-life | Receptor location | Latency of effect | Stored? |
|---|---|---|---|---|---|---|
| Peptide / protein | Insulin, glucagon, PTH, GH, ADH, oxytocin, ACTH, calcitonin, leptin, ANP | Dissolved, free | 3–30 min | Plasma membrane | Seconds to minutes | Yes — in secretory vesicles, released on demand |
| Glycoprotein | TSH, FSH, LH, hCG | Dissolved, free | 30 min–several h | Plasma membrane | Minutes | Yes |
| Catecholamine (amine) | Epinephrine, norepinephrine, dopamine | Dissolved, free | 1–3 min | Plasma membrane | Seconds | Yes — chromaffin granules |
| Thyroid hormone (amine, iodinated) | T₄, T₃ | >99% bound (TBG, transthyretin, albumin) | T₄ ≈ 7 days; T₃ ≈ 1 day | Nucleus | Hours to days | Yes — colloid, months of supply |
| Steroid | Cortisol, aldosterone, testosterone, estradiol, progesterone, calcitriol | 90–98% bound (CBG, SHBG, albumin, DBP) | 20 min (aldosterone) to hours | Cytoplasm/nucleus | 30 min to days | No — synthesized on demand from cholesterol |
| Eicosanoid (local) | Prostaglandins, leukotrienes, thromboxane | Acts locally; degraded in one pass through lung | Seconds | Plasma membrane | Seconds | No |
Two consequences worth memorizing because they are asked constantly. First, steroid hormones cannot be stored, so a gland that must raise steroid output must raise synthesis, which is why steroid responses take at least half an hour and why chronic stimulation causes gland hypertrophy rather than just faster release. Second, only free hormone is active; protein-bound hormone is a circulating reservoir. This is why pregnancy, which raises thyroxine-binding globulin, raises total T₄ while leaving free T₄ and the patient euthyroid — and why total hormone assays mislead and free assays do not.
F.2 Master table
Chapter numbers in the final column give the chapter where the hormone is developed, not merely mentioned.
Hypothalamic releasing and inhibiting hormones
All are peptides, all travel the short hypophyseal portal system to the anterior pituitary in high concentration, and all are secreted in pulses — a fact that matters clinically, because continuous administration of GnRH paradoxically shuts the axis down.
| Hormone | Source | Chemical class | Target | Principal actions | Stimulus for release | Inhibition | Ch. |
|---|---|---|---|---|---|---|---|
| TRH (thyrotropin-releasing hormone) | Hypothalamus, paraventricular nucleus | Peptide (3 aa) | Anterior pituitary thyrotrophs | Stimulates TSH release; also stimulates prolactin | Cold exposure, low circulating T₃/T₄ | T₃/T₄ negative feedback | 14 |
| CRH (corticotropin-releasing hormone) | Hypothalamus, paraventricular nucleus | Peptide (41 aa) | Anterior pituitary corticotrophs | Stimulates ACTH release | Physical/psychological stress, hypoglycemia, circadian drive peaking before waking | Cortisol negative feedback | 14 |
| GnRH (gonadotropin-releasing hormone) | Hypothalamus, arcuate/preoptic | Peptide (10 aa) | Anterior pituitary gonadotrophs | Pulsatile release drives FSH and LH; pulse frequency selects which | Kisspeptin signaling; adequate leptin/energy stores; puberty | Testosterone, estradiol, progesterone, inhibin (indirectly) | 14, 23 |
| GHRH (growth hormone-releasing hormone) | Hypothalamus, arcuate nucleus | Peptide (44 aa) | Anterior pituitary somatotrophs | Stimulates GH synthesis and release | Deep (slow-wave) sleep, hypoglycemia, exercise, high protein meal, ghrelin | Somatostatin, IGF-1, free fatty acids, hyperglycemia | 14 |
| Somatostatin (GHIH) | Hypothalamus, periventricular; also pancreatic delta cells and gut D cells | Peptide (14/28 aa) | Somatotrophs, thyrotrophs, islet cells, gut | Inhibits GH and TSH; inhibits insulin, glucagon, gastrin, secretin; slows gut motility and secretion | Rising GH, rising glucose, gut nutrients | Universal "off switch" — few inhibitors | 14, 20 |
| Dopamine (PIH, prolactin-inhibiting hormone) | Hypothalamus, arcuate nucleus | Catecholamine | Anterior pituitary lactotrophs | Tonically inhibits prolactin release — the only anterior pituitary hormone under dominant inhibitory control | Continuous baseline tone | Suckling, TRH, estrogen, dopamine antagonist drugs | 14 |
Clinical Connection · Why a stalk injury raises only one hormone
Because prolactin is the one anterior pituitary hormone held down by tonic inhibition rather than driven up by stimulation, anything that severs the portal connection — a pituitary stalk transection, a large non-secreting mass compressing the stalk — produces a distinctive pattern: every anterior pituitary hormone falls except prolactin, which rises. A mildly elevated prolactin with low TSH, ACTH, and gonadotropins is therefore not a prolactinoma; it is the "stalk effect," and the tumor is usually not the one making the hormone. This is a clean example of a general rule — knowing the sign of a control signal predicts the shape of the failure.
Anterior pituitary
Six hormones from five cell types. Three are tropic (they command other endocrine glands) and three act directly on non-endocrine tissue.
| Hormone | Source | Chemical class | Target | Principal actions | Stimulus for release | Inhibition | Ch. |
|---|---|---|---|---|---|---|---|
| TSH (thyrotropin) | Thyrotrophs | Glycoprotein | Thyroid follicular cells | Stimulates iodide trapping, thyroglobulin synthesis, T₃/T₄ release, and follicular growth | TRH; cold | T₃/T₄ (potent), somatostatin, glucocorticoids, dopamine | 14 |
| ACTH (corticotropin) | Corticotrophs | Peptide (39 aa), cleaved from POMC | Adrenal cortex, zona fasciculata and reticularis | Stimulates cortisol and adrenal androgen synthesis; trophic to the cortex; incidentally stimulates melanocytes at high levels | CRH; stress; circadian peak 06:00–08:00 | Cortisol negative feedback | 14 |
| FSH (follicle-stimulating hormone) | Gonadotrophs | Glycoprotein | Ovarian granulosa cells; testicular Sertoli cells | Female: recruits follicles, drives granulosa aromatase and estradiol synthesis. Male: supports spermatogenesis and androgen-binding protein | GnRH pulses (slower frequency favors FSH) | Inhibin B (selectively), estradiol, testosterone | 14, 23 |
| LH (luteinizing hormone) | Gonadotrophs | Glycoprotein | Ovarian theca cells and corpus luteum; testicular Leydig cells | Female: theca androgen synthesis; the mid-cycle surge triggers ovulation; maintains corpus luteum. Male: testosterone synthesis | GnRH pulses (faster frequency favors LH); sustained high estradiol produces the pre-ovulatory surge by positive feedback | Testosterone, progesterone | 14, 23 |
| GH (growth hormone, somatotropin) | Somatotrophs | Peptide (191 aa) | Liver (→ IGF-1), bone, muscle, adipose | Direct: lipolysis, insulin antagonism, amino acid uptake. Indirect via IGF-1: epiphyseal plate growth, protein synthesis, organ growth | GHRH, ghrelin, sleep, exercise, fasting, hypoglycemia, protein meal | Somatostatin, IGF-1, hyperglycemia, obesity, glucocorticoids | 14, 6 |
| Prolactin (PRL) | Lactotrophs | Peptide (199 aa) | Mammary alveolar cells; gonadotrophs | Drives milk synthesis (not ejection); suppresses GnRH, hence lactational amenorrhea | Suckling, TRH, estrogen, pregnancy, sleep, stress | Dopamine (dominant) | 14, 24 |
Posterior pituitary
Not a gland. The posterior pituitary is the axon terminals of hypothalamic neurons whose cell bodies sit in the supraoptic and paraventricular nuclei; the hormones are made in the hypothalamus and stored downstream. This is neurosecretion, and it explains why the posterior lobe has no portal system and no releasing hormones.
| Hormone | Source | Chemical class | Target | Principal actions | Stimulus for release | Inhibition | Ch. |
|---|---|---|---|---|---|---|---|
| ADH (antidiuretic hormone, vasopressin) | Supraoptic nucleus → posterior pituitary | Peptide (9 aa) | Renal collecting duct (V₂), vascular smooth muscle (V₁) | Inserts aquaporin-2 channels into the collecting duct apical membrane, reabsorbing water without solute; at higher concentrations, vasoconstriction | Rise in plasma osmolality of as little as 1% (osmoreceptors); ≥10% fall in blood volume or pressure (baroreceptors); nausea, pain, nicotine | Low osmolality, volume expansion, alcohol, ANP | 14, 22, 27 |
| Oxytocin | Paraventricular nucleus → posterior pituitary | Peptide (9 aa) | Uterine myometrium, mammary myoepithelial cells, brain | Uterine contraction during labor; milk ejection (let-down); social bonding behaviors | Cervical stretch (positive feedback in labor), suckling, estrogen priming | Progesterone during pregnancy; withdrawal of stimulus | 14, 24 |
Thyroid and parathyroid
| Hormone | Source | Chemical class | Target | Principal actions | Stimulus for release | Inhibition | Ch. |
|---|---|---|---|---|---|---|---|
| T₄ (thyroxine) | Thyroid follicular cells | Iodinated amine, lipid-soluble | Nearly every nucleated cell | A prohormone: 80% of circulating T₃ comes from peripheral 5′-deiodination of T₄. Long half-life buffers supply | TSH | T₃/T₄ feedback on TRH and TSH; iodine excess (Wolff–Chaikoff) | 14 |
| T₃ (triiodothyronine) | Thyroid (20%) and peripheral conversion (80%) | Iodinated amine, lipid-soluble | Nuclear thyroid hormone receptor in nearly every cell | Raises basal metabolic rate and heat production; increases Na⁺/K⁺-ATPase density; permissive for catecholamines (upregulates β-receptors); required for normal CNS development and linear growth | TSH; adequate dietary iodine | Same feedback loop; illness suppresses conversion ("low T₃ syndrome") | 14 |
| Calcitonin | Thyroid parafollicular (C) cells | Peptide (32 aa) | Osteoclasts, kidney | Inhibits osteoclast activity, lowering plasma calcium; increases urinary calcium loss. Physiologically minor in adult humans — thyroidectomy causes no calcium disorder | Rising plasma Ca²⁺ | Falling plasma Ca²⁺ | 14, 6 |
| PTH (parathyroid hormone) | Parathyroid chief cells | Peptide (84 aa) | Bone, kidney, (indirectly) intestine | Raises plasma Ca²⁺ three ways: stimulates osteoclastic resorption via RANKL on osteoblasts, increases distal tubule Ca²⁺ reabsorption, and activates renal 1α-hydroxylase to make calcitriol. Also lowers plasma phosphate by inhibiting proximal tubule phosphate reabsorption | Fall in ionized Ca²⁺ detected by the calcium-sensing receptor; rise in phosphate; low calcitriol | Rising ionized Ca²⁺, calcitriol, severe hypomagnesemia (which paradoxically blocks release) | 14, 6, 22 |
Adrenal cortex and medulla
The cortex is three zones, and the mnemonic that matters is that they run outside-in with their products: salt, sugar, sex — glomerulosa/aldosterone, fasciculata/cortisol, reticularis/androgens. The medulla is not cortex at all; it is a modified sympathetic ganglion whose postganglionic neurons lost their axons and secrete into blood.
| Hormone | Source | Chemical class | Target | Principal actions | Stimulus for release | Inhibition | Ch. |
|---|---|---|---|---|---|---|---|
| Aldosterone | Zona glomerulosa | Steroid (mineralocorticoid) | Renal distal tubule and collecting duct principal cells; colon, sweat and salivary glands | Increases Na⁺ reabsorption (and therefore water) while increasing K⁺ and H⁺ secretion; the final effector of the RAAS; expands extracellular fluid volume and raises blood pressure | Angiotensin II, hyperkalemia (direct and potent), ACTH (weakly, permissively) | ANP/BNP, hypokalemia, volume expansion | 14, 22, 27 |
| Cortisol | Zona fasciculata | Steroid (glucocorticoid) | Nearly all tissues | Raises blood glucose by gluconeogenesis, proteolysis, and lipolysis; permissive for catecholamine vasoconstriction; suppresses immune and inflammatory responses; inhibits bone formation and collagen synthesis; strong circadian rhythm peaking near waking | ACTH; physical and psychological stress; hypoglycemia; circadian drive | Negative feedback on CRH and ACTH; exogenous glucocorticoids | 14, 21 |
| Adrenal androgens (DHEA, DHEA-S, androstenedione) | Zona reticularis | Steroid | Peripheral tissues that convert them to testosterone/estradiol | Minor in adult males; in females the principal source of androgen driving pubic and axillary hair (adrenarche) and contributing to libido | ACTH | ACTH suppression | 14, 23 |
| Epinephrine (~80%) | Adrenal medulla chromaffin cells | Catecholamine | β₁ (heart), β₂ (bronchi, skeletal muscle vessels, liver), α₁ (most vessels) | Raises heart rate and contractility, dilates bronchi and skeletal muscle arterioles, constricts splanchnic and cutaneous vessels, mobilizes glucose and free fatty acids. The circulating arm of the sympathetic response | Preganglionic sympathetic fibers (acetylcholine on nicotinic receptors); stress, exercise, hypoglycemia, hypotension | Withdrawal of sympathetic drive; rapid enzymatic degradation (COMT, MAO) | 14, 12 |
| Norepinephrine (~20%) | Adrenal medulla | Catecholamine | Predominantly α₁ and α₂; weak β₂ | Widespread vasoconstriction, raising total peripheral resistance and mean arterial pressure; reflex bradycardia may follow | Same as epinephrine | Same | 14, 12, 17 |
Clinical Connection · Cortisol's permissive role, seen by its absence
A patient in adrenal crisis is hypotensive and does not respond normally to norepinephrine — you can infuse a vasopressor and the pressure barely moves. Give hydrocortisone and the same vasopressor now works. Cortisol does not itself constrict vessels; it maintains the expression of α₁-adrenergic receptors and the enzymes downstream of them. This is what permissive means in endocrinology: hormone A does not produce the effect but is required for hormone B to produce it. Thyroid hormone is permissive for catecholamines in the same way, which is why untreated hypothyroidism blunts the tachycardic response to stress and thyrotoxicosis exaggerates it.
Pancreatic islets
Roughly one to two million islets, about 1–2% of pancreatic mass, with an internal blood supply arranged so that beta cell products bathe the alpha cells downstream — an anatomical detail with a physiological point: insulin directly restrains glucagon.
| Hormone | Source | Chemical class | Target | Principal actions | Stimulus for release | Inhibition | Ch. |
|---|---|---|---|---|---|---|---|
| Insulin | Beta cells (≈65% of islet) | Peptide (51 aa, two chains, from proinsulin; C-peptide co-secreted 1:1) | Liver, skeletal muscle, adipose (GLUT4 tissues) | Lowers blood glucose: inserts GLUT4 transporters in muscle and fat, drives glycogenesis, lipogenesis, and protein synthesis, and suppresses gluconeogenesis, glycogenolysis, lipolysis, and ketogenesis. Drives K⁺ into cells | Rising blood glucose (>90 mg/dL, 5.0 mmol/L); amino acids; GIP and GLP-1 from the gut (the incretin effect); parasympathetic tone | Sympathetic α₂ stimulation, somatostatin, low glucose | 14, 21 |
| Glucagon | Alpha cells (≈20%) | Peptide (29 aa) | Liver, primarily | Raises blood glucose: glycogenolysis, gluconeogenesis, ketogenesis. Insulin's mirror image, and the first-line defense against hypoglycemia | Falling blood glucose (<70 mg/dL, 3.9 mmol/L); amino acids after a protein meal; sympathetic stimulation; exercise | Insulin, somatostatin, hyperglycemia, free fatty acids | 14, 21 |
| Somatostatin | Delta cells (≈8%) | Peptide | Alpha and beta cells; gut | Paracrine brake on both insulin and glucagon; slows nutrient absorption | Rising glucose, amino acids, fatty acids in the gut | — | 14, 20 |
| Pancreatic polypeptide | F (PP) cells | Peptide | Gallbladder, exocrine pancreas | Reduces exocrine pancreatic secretion and gallbladder contraction; contributes to satiety | Protein meal, vagal stimulation | Somatostatin | 14, 20 |
| Amylin | Beta cells, co-secreted with insulin | Peptide (37 aa) | Brain, stomach | Slows gastric emptying, suppresses postprandial glucagon, promotes satiety | Same stimuli as insulin | Same as insulin | 21 |
Gonadal
| Hormone | Source | Chemical class | Target | Principal actions | Stimulus for release | Inhibition | Ch. |
|---|---|---|---|---|---|---|---|
| Testosterone | Testicular Leydig cells; ovary and adrenal in small amounts | Steroid (androgen) | Reproductive tract, skeletal muscle, bone, larynx, skin, CNS | Male secondary sexual characteristics; drives spermatogenesis at high intratesticular concentration; anabolic to muscle and bone; closes epiphyseal plates after aromatization to estradiol; maintains libido in both sexes | LH | Negative feedback on GnRH and LH | 23 |
| Dihydrotestosterone (DHT) | Peripheral tissues via 5α-reductase | Steroid | Prostate, external genitalia, hair follicles | The more potent androgen at the receptor; responsible for external genital development, prostate growth, and male-pattern hair changes | Availability of testosterone and 5α-reductase | 5α-reductase inhibition | 23, 24 |
| Estradiol (E₂) | Ovarian granulosa cells (aromatase acting on theca-derived androgens); placenta; adipose | Steroid | Uterus, breast, bone, vessels, brain, liver | Proliferative phase endometrial growth; female secondary sexual characteristics; inhibits osteoclast activity (its loss at menopause accelerates bone loss); raises HDL and lowers LDL; produces the pre-ovulatory LH surge by positive feedback when sustained and high | FSH acting on granulosa cells | Negative feedback on FSH/LH at low-to-moderate levels | 23, 6, 26 |
| Progesterone | Corpus luteum; placenta after ~10 weeks | Steroid | Endometrium, myometrium, breast, brain | Converts proliferative endometrium to secretory; quiets the myometrium; thickens cervical mucus; raises basal body temperature ~0.3–0.5 °C after ovulation; prepares breast alveoli | LH maintains the corpus luteum; hCG maintains it in pregnancy | Luteolysis if no hCG appears | 23, 24 |
| Inhibin B / Inhibin A | Sertoli cells; granulosa cells and corpus luteum | Glycoprotein | Anterior pituitary gonadotrophs | Selectively suppresses FSH without affecting LH — the mechanism that lets the body regulate gamete production separately from steroid production | FSH stimulation; presence of developing gametes | Falls when germ cells are lost | 23 |
| Anti-Müllerian hormone (AMH) | Fetal Sertoli cells; adult granulosa cells | Glycoprotein | Müllerian ducts; ovarian follicles | Fetal: causes regression of the Müllerian (paramesonephric) ducts in males. Adult female: a clinical marker of ovarian reserve | Constitutive in fetal testis | Declines with follicle depletion | 23, 24 |
Placental
The placenta is a temporary endocrine organ that outproduces every other gland in the body, and its hormones explain most of the physiology of pregnancy.
| Hormone | Source | Chemical class | Target | Principal actions | Stimulus for release | Inhibition | Ch. |
|---|---|---|---|---|---|---|---|
| hCG (human chorionic gonadotropin) | Syncytiotrophoblast | Glycoprotein | Corpus luteum (LH receptor) | Rescues the corpus luteum so it keeps making progesterone until the placenta takes over at ~10 weeks; the molecule detected by pregnancy tests, present ~8 days after fertilization | Implantation of the blastocyst | Peaks at 8–10 weeks, then declines | 24 |
| Human placental lactogen (hPL) | Syncytiotrophoblast | Peptide, GH-like | Maternal liver, muscle, adipose | Induces maternal insulin resistance, shunting glucose to the fetus; mobilizes maternal free fatty acids as an alternative maternal fuel. The reason gestational diabetes exists | Rises with placental mass through pregnancy | Delivery of the placenta | 24 |
| Placental estrogens (mostly estriol) | Placenta using fetal adrenal DHEA-S | Steroid | Uterus, breast, maternal cardiovascular system | Uterine growth, breast development, increased uterine blood flow, increased hepatic synthesis of binding proteins and clotting factors | Fetal adrenal precursor supply | Delivery | 24 |
| Placental progesterone | Placenta after ~10 weeks | Steroid | Myometrium, immune system | Maintains uterine quiescence; contributes to maternal immune tolerance of the fetus | Placental mass | Delivery — the abrupt fall triggers lactogenesis II | 24 |
| Relaxin | Corpus luteum, placenta, decidua | Peptide | Pelvic ligaments, cervix, vasculature | Softens the cervix and pelvic ligaments; contributes to the increase in maternal cardiac output and renal plasma flow | Pregnancy | Delivery | 24 |
Pineal and thymic
| Hormone | Source | Chemical class | Target | Principal actions | Stimulus for release | Inhibition | Ch. |
|---|---|---|---|---|---|---|---|
| Melatonin | Pineal gland | Amine (from tryptophan via serotonin) | Suprachiasmatic nucleus, peripheral clocks | Signals biological night; entrains circadian rhythm; promotes sleep onset; falls with age | Darkness, via retina → SCN → superior cervical ganglion → pineal | Light, especially short-wavelength light in the evening; beta-blockers | 14, 11, 26 |
| Thymosins / thymopoietin | Thymic epithelial cells | Peptides | Developing T lymphocytes | Support T-cell maturation, positive and negative selection in the thymic cortex and medulla | Thymic activity, maximal before puberty | Thymic involution after puberty; glucocorticoids | 18 |
Hormones from organs that are not glands
This is the section students underestimate, and it is where the integration questions come from. Every organ below has a day job and a hormone on the side, and the hormone almost always defends the variable the day job is about.
| Hormone | Source | Chemical class | Target | Principal actions | Stimulus for release | Inhibition | Ch. |
|---|---|---|---|---|---|---|---|
| ANP (atrial natriuretic peptide) | Atrial myocytes | Peptide (28 aa) | Kidney, vessels, adrenal | Increases GFR and Na⁺ excretion; vasodilates; inhibits renin, aldosterone, and ADH. The physiological antagonist of the RAAS | Atrial stretch from volume expansion | Low filling pressures | 16, 22, 27 |
| BNP (B-type natriuretic peptide) | Ventricular myocytes | Peptide (32 aa) | Same as ANP | Same actions as ANP; because ventricular stretch reflects ventricular wall stress, plasma BNP is a clinical marker of heart failure | Ventricular wall stress and stretch | Falling filling pressures | 16, 17 |
| Erythropoietin (EPO) | Renal peritubular interstitial fibroblasts (85%); liver (15%) | Glycoprotein | Bone marrow erythroid progenitors | Stimulates proliferation and survival of proerythroblasts, raising red cell production over 3–5 days | Renal tissue hypoxia — low arterial O₂, anemia, altitude, high androgens | Correction of hypoxia; renal parenchymal loss (the mechanism of anemia in chronic kidney disease); inflammation | 15, 22 |
| Renin | Renal juxtaglomerular (granular) cells | Enzyme (protease), not strictly a hormone | Circulating angiotensinogen | Cleaves angiotensinogen to angiotensin I, initiating the RAAS; the rate-limiting step of the whole cascade | Fall in renal perfusion pressure; low NaCl at the macula densa; β₁ sympathetic stimulation | Angiotensin II (short-loop feedback), ANP, high NaCl delivery, volume expansion, beta-blockers | 22, 17, 27 |
| Angiotensin II | Plasma; converted by ACE, chiefly in pulmonary capillary endothelium | Peptide (8 aa) | Arterioles, adrenal glomerulosa, kidney, hypothalamus | Potent vasoconstrictor (raises TPR); stimulates aldosterone; stimulates proximal tubule Na⁺ reabsorption; constricts the efferent arteriole to preserve GFR; stimulates thirst and ADH | Renin availability | ACE inhibitors, ARBs, volume expansion | 17, 22, 27 |
| Calcitriol (1,25-dihydroxyvitamin D₃) | Kidney proximal tubule (1α-hydroxylase) acting on liver 25-OH-D | Steroid | Small intestine, bone, kidney, parathyroid | Increases intestinal absorption of calcium and phosphate — the only mechanism that adds net calcium to the body; supports bone mineralization; suppresses PTH | PTH, low plasma phosphate, low calcium | FGF23, high calcitriol (feedback on 1α-hydroxylase), renal failure | 6, 22 |
| Gastrin | G cells, gastric antrum | Peptide | Parietal cells, ECL cells, gastric smooth muscle | Stimulates gastric acid secretion (chiefly by releasing histamine from ECL cells), gastric motility, and mucosal growth | Peptides and amino acids in the stomach, gastric distension, vagal stimulation | Antral pH below 3 (a clean negative feedback loop), somatostatin, secretin | 20 |
| Secretin | S cells, duodenum | Peptide (27 aa) | Pancreatic duct cells, liver, stomach | Stimulates bicarbonate-rich pancreatic and biliary secretion, neutralizing duodenal chyme; inhibits gastrin and gastric emptying | Acid (pH < 4.5) in the duodenum | Rising duodenal pH | 20 |
| CCK (cholecystokinin) | I cells, duodenum and jejunum | Peptide | Gallbladder, pancreatic acinar cells, sphincter of Oddi, stomach, vagal afferents | Contracts the gallbladder, relaxes the sphincter of Oddi, stimulates enzyme-rich pancreatic secretion, slows gastric emptying, produces satiety | Fatty acids and amino acids in the duodenum | Removal of the stimulus; trypsin feedback | 20, 21 |
| GIP (glucose-dependent insulinotropic peptide) | K cells, duodenum and jejunum | Peptide | Pancreatic beta cells | An incretin: potentiates glucose-stimulated insulin release before glucose is absorbed, which is why oral glucose raises insulin more than intravenous glucose at the same blood level | Glucose and fat in the small intestine | Absence of luminal nutrients | 20, 21 |
| GLP-1 (glucagon-like peptide 1) | L cells, ileum and colon | Peptide | Beta cells, stomach, hypothalamus | The second incretin: potentiates insulin release, suppresses glucagon, slows gastric emptying, increases satiety | Nutrients in the distal small intestine | Rapid degradation by DPP-4 | 20, 21 |
| Motilin | M cells, duodenum and jejunum | Peptide | GI smooth muscle | Generates the migrating motor complex, the housekeeping wave that sweeps the fasting gut every 90–120 minutes | Fasting; cyclic release between meals | Feeding | 20 |
| Ghrelin | Gastric fundus (X/A-like cells) | Peptide (28 aa, acylated) | Hypothalamic arcuate nucleus; pituitary somatotrophs | The hunger signal: rises before meals, stimulates appetite, and stimulates GH release | Fasting, empty stomach, anticipation of a meal | Gastric distension and nutrient intake; the only orexigenic gut hormone in common use | 20, 21 |
| Leptin | Adipocytes, in proportion to fat mass | Peptide (167 aa) | Hypothalamic arcuate nucleus | Long-term adiposity signal: suppresses appetite (via POMC neurons), raises energy expenditure, and permits reproductive function by supporting GnRH pulsatility | Increasing fat mass; insulin; feeding | Fasting and weight loss, which lower leptin and defend the old weight — the reason weight regain is physiologically driven | 21, 14, 23 |
| Adiponectin | Adipocytes, inversely with fat mass | Protein | Liver, skeletal muscle | Increases insulin sensitivity and fatty acid oxidation; anti-inflammatory and anti-atherogenic. Falls in obesity, contributing to insulin resistance | Lean adipose tissue, exercise, weight loss | Visceral adiposity, inflammation (TNF-α, IL-6) | 21 |
| Osteocalcin (undercarboxylated) | Osteoblasts | Peptide | Pancreatic beta cells, muscle, testis | Bone's endocrine output: increases insulin secretion and sensitivity; a marker of bone formation rate | Osteoblast activity; bone resorption releases it | Low bone turnover; bisphosphonates | 6, 21 |
| FGF23 (fibroblast growth factor 23) | Osteocytes | Protein | Kidney proximal tubule, parathyroid | The phosphaturic hormone: increases urinary phosphate excretion and suppresses calcitriol synthesis. Rises early in chronic kidney disease, before phosphate does | High plasma phosphate, high calcitriol | Low phosphate | 6, 22 |
F.3 The three-tier axes
Four of the endocrine system's control loops share one architecture. Learn the architecture once and you have learned four systems, plus the diagnostic method in §F.5.
THE THREE-TIER ENDOCRINE AXIS — one pattern, four instances
TIER 1 ┌────────────────────────────────────────┐
HYPO- │ HYPOTHALAMUS │◄──────────────┐
THALAMUS │ releasing hormone · PULSATILE · tiny │ │
│ amounts · never reaches systemic blood│ │
└──────────────────┬─────────────────────┘ │
│ hypophyseal PORTAL veins │
▼ (short trip, very high [ ]) │
TIER 2 ┌────────────────────────────────────────┐ LONG │
ANTERIOR │ ANTERIOR PITUITARY │◄────────┐LOOP │
PITUITARY │ TROPIC hormone → systemic circulation │ │ (−) │
└──────────────────┬─────────────────────┘ SHORT │ │
│ LOOP │ │
▼ (−) │ │
TIER 3 ┌────────────────────────────────────────┐ │ │
TARGET │ TARGET GLAND │─────────┘ │
GLAND │ EFFECTOR hormone → every tissue │───────────────┘
└──────────────────┬─────────────────────┘
▼
TISSUE EFFECT = the DEFENDED VARIABLE
(also the thing the patient feels)
══════════════════════════════════════════════════════════════════════
AXIS TIER 1 TIER 2 TIER 3 DEFENDS
──────────────────────────────────────────────────────────────────────
HPT TRH → TSH → T₄ → T₃ metabolic rate,
heat production
HPA CRH → ACTH → CORTISOL plasma glucose,
stress response
HPG ♂ GnRH → LH → TESTOSTERONE spermatogenesis
(pulses) → FSH → (inhibin B) gamete number
HPG ♀ GnRH → FSH → LH → ESTRADIOL → ovulation, the
(pulses) surge PROGESTERONE endometrial cycle
GH axis GHRH (+) → GH → IGF-1 (liver) linear growth,
SST (−) fuel partitioning
──────────────────────────────────────────────────────────────────────
THE ONE PLACE THIS BREAKS: ovulation. Sustained HIGH estradiol for
~36 h flips the pituitary from negative to POSITIVE feedback, producing
the LH surge. Same hormone, same receptor, opposite sign — because the
variable being defended has changed from "steady state" to "fire once."
Figure F.1 — The generic three-tier endocrine axis and its four instances.
Described: A vertical three-tier diagram. The top tier is the hypothalamus, which releases a pulsatile releasing hormone in tiny amounts into the hypophyseal portal veins; because the trip is short, concentration at the target is very high and the hormone never appears in meaningful quantity in systemic blood. The middle tier is the anterior pituitary, which releases a tropic hormone into the systemic circulation. The bottom tier is the target gland, which releases an effector hormone that acts on every tissue and sets the defended variable. Two inhibitory feedback arrows run upward: a short loop from the target gland to the pituitary and a long loop from the target gland to the hypothalamus. Beneath the diagram, a table maps five axes onto the three tiers: the hypothalamic-pituitary-thyroid axis runs TRH to TSH to thyroxine and triiodothyronine, defending metabolic rate and heat production; the hypothalamic-pituitary-adrenal axis runs CRH to ACTH to cortisol, defending plasma glucose and the stress response; the male gonadal axis runs GnRH to LH to testosterone, with FSH and inhibin B controlling gamete number; the female gonadal axis runs GnRH to FSH and the LH surge to estradiol and progesterone, controlling ovulation and the endometrial cycle; and the growth hormone axis runs GHRH, opposed by somatostatin, to growth hormone to hepatic IGF-1, defending linear growth and fuel partitioning. A closing note records the single exception: sustained high estradiol for about thirty-six hours converts pituitary feedback from negative to positive, producing the ovulatory LH surge.
What each loop actually controls
HPA. Cortisol feeds back on both CRH and ACTH. Because the axis has a strong circadian drive peaking just before waking, a single random cortisol value is nearly uninterpretable; timing is everything. Exogenous glucocorticoids suppress the whole axis, which is why steroids are tapered rather than stopped — the atrophied adrenal cortex needs weeks to recover.
HPT. T₃ and T₄ feed back on both tiers, and TSH is exquisitely sensitive: a small fall in free T₄ produces a large, logarithmic rise in TSH. That amplification is what makes TSH the best single screening test in all of endocrinology, and it is why TSH moves before free T₄ does in early disease (the "subclinical" state).
HPG. Two hormones, two feedback signals. Sex steroids restrain LH; inhibin selectively restrains FSH. This division exists because the gonad has two jobs — making steroids and making gametes — and the body needs to regulate them independently. It is also why a man with damaged seminiferous tubules but intact Leydig cells has a high FSH with a normal LH and normal testosterone.
GH axis. The only axis with a dedicated inhibitory hypothalamic hormone as well as a stimulatory one, and the only one whose effector hormone (IGF-1) is made by the liver rather than an endocrine gland. GH is secreted in large pulses, mostly during slow-wave sleep, so random GH levels are useless; IGF-1, which is stable across the day, is the practical measure.
F.4 Excess and deficiency: what each hormone looks like when it goes wrong
The fastest way to consolidate a hormone's actions is to read them in both directions. Every row below is the same physiology stated twice.
| Hormone | Deficiency | Excess |
|---|---|---|
| GH (child) | Pituitary dwarfism — proportionate short stature, normal intelligence | Gigantism — excessive linear growth before epiphyseal closure |
| GH (adult) | Reduced lean mass, central adiposity, low bone density, poor quality of life | Acromegaly — enlarged hands, feet, jaw, and tongue; insulin resistance; hypertension; cardiomyopathy |
| ADH | Diabetes insipidus — large volumes of dilute urine, hypernatremia, intense thirst | SIADH — water retention, concentrated urine, hyponatremia with normal volume |
| Thyroid hormone | Hypothyroidism — cold intolerance, weight gain, bradycardia, constipation, fatigue, dry skin, delayed reflex relaxation; cretinism in infancy | Thyrotoxicosis — heat intolerance, weight loss despite appetite, tachycardia and atrial fibrillation, tremor, anxiety, diarrhea |
| PTH | Hypoparathyroidism — hypocalcemia, tetany, Chvostek and Trousseau signs, prolonged QT | Hyperparathyroidism — hypercalcemia, kidney stones, bone pain, constipation, confusion ("stones, bones, groans, and psychiatric overtones") |
| Calcitriol / vitamin D | Rickets (child) or osteomalacia (adult) — undermineralized bone, secondary hyperparathyroidism | Hypercalcemia, hypercalciuria, soft-tissue calcification |
| Cortisol | Addison disease — fatigue, weight loss, hypotension, hypoglycemia, hyponatremia with hyperkalemia, hyperpigmentation if primary | Cushing syndrome — central obesity with thin limbs, moon face, purple striae, muscle wasting, hyperglycemia, hypertension, osteoporosis, immunosuppression |
| Aldosterone | Hypotension, hyponatremia, hyperkalemia, metabolic acidosis | Conn syndrome — hypertension, hypokalemia, metabolic alkalosis, suppressed renin |
| Insulin | Type 1 diabetes — hyperglycemia, polyuria, polydipsia, weight loss, ketoacidosis | Hypoglycemia — sweating, tremor, confusion, seizure; hypokalemia |
| Glucagon | Impaired recovery from hypoglycemia | Hyperglycemia; the necrolytic rash of glucagonoma |
| Epinephrine | Little effect (sympathetic nerves compensate) | Pheochromocytoma — episodic headache, palpitations, sweating, severe paroxysmal hypertension |
| Testosterone | Loss of libido, reduced muscle and bone mass, infertility, gynecomastia | Acne, polycythemia, testicular atrophy from feedback suppression, aggression |
| Estradiol | Amenorrhea, vasomotor symptoms, accelerated bone loss, vaginal atrophy, adverse lipid shift | Endometrial hyperplasia, breast tenderness, thromboembolic risk |
| Prolactin | Failure of lactation | Galactorrhea, amenorrhea in women, hypogonadism and low libido in men — because prolactin suppresses GnRH |
| EPO | Anemia of chronic kidney disease — normocytic, normochromic, with a low reticulocyte count | Polycythemia, raised hematocrit and viscosity, thrombotic risk |
Clinical Connection · Reading the potassium tells you the zone
Adrenal insufficiency comes in two flavors, and one laboratory value separates them. In primary adrenal failure the whole cortex is destroyed, so aldosterone is lost along with cortisol: the patient cannot excrete potassium normally and presents with hyponatremia and hyperkalemia, plus hyperpigmentation from the melanocyte-stimulating fragment of the POMC precursor that ACTH is cleaved from. In secondary adrenal failure the pituitary is at fault, ACTH is low, and only the ACTH-dependent zones (fasciculata and reticularis) atrophy. The zona glomerulosa is driven mainly by angiotensin II and potassium, not ACTH, so aldosterone is preserved: no hyperkalemia, no hyperpigmentation. One electrolyte, one anatomical fact about which zone answers to which signal, and the lesion is localized.
F.5 Localizing an endocrine lesion
Here is the single most useful diagnostic rule in endocrinology, and it follows directly from the loop diagram in §F.1:
Never measure a hormone alone. Measure the hormone and its tropic hormone together, and read the pair. In primary disease (the target gland is at fault) the two move in opposite directions, because feedback is intact and the pituitary is reacting correctly to a broken gland. In secondary disease (the pituitary is at fault) they move in the same direction, because the pituitary is the thing that is broken.
Terminology, so the labels stay straight:
| Term | Broken tier | Tropic hormone behavior |
|---|---|---|
| Primary | Tier 3 — the target gland itself | Moves opposite to the effector hormone (feedback intact and appropriate) |
| Secondary | Tier 2 — the anterior pituitary | Moves in the same direction as the effector hormone (inappropriately normal or low) |
| Tertiary | Tier 1 — the hypothalamus | Same pattern as secondary; distinguished only by stimulation testing or imaging |
Worked decision table · Thyroid axis (measure TSH + free T₄)
| TSH | Free T₄ | Interpretation | Typical cause |
|---|---|---|---|
| High | Low | Primary hypothyroidism — gland failed, pituitary shouting | Hashimoto thyroiditis; iodine deficiency; post-ablation |
| High | Normal | Subclinical hypothyroidism — TSH moves first | Early Hashimoto |
| Low | Low | Central (secondary or tertiary) hypothyroidism — pituitary silent when it should shout | Pituitary macroadenoma, Sheehan syndrome, hypothalamic disease |
| Low | High | Primary hyperthyroidism — gland autonomous, pituitary correctly suppressed | Graves disease; toxic nodule |
| Low | Normal | Subclinical hyperthyroidism | Autonomous nodule; overtreatment with levothyroxine |
| High or normal | High | Inappropriate TSH — the pituitary is not obeying feedback | TSH-secreting adenoma; thyroid hormone resistance |
Worked decision table · Adrenal axis (measure 08:00 cortisol + ACTH)
| Cortisol | ACTH | Interpretation | Extra clue |
|---|---|---|---|
| Low | High | Primary adrenal insufficiency (Addison) | Hyperkalemia, hyponatremia, hyperpigmentation |
| Low | Low or "normal" | Secondary/tertiary adrenal insufficiency | Normal potassium, no pigmentation; other pituitary deficits; recent steroid taper |
| High | Low | ACTH-independent Cushing | Adrenal adenoma or carcinoma; or exogenous steroid, in which case cortisol assays may also be low while the patient looks Cushingoid |
| High | High or normal | ACTH-dependent Cushing | Pituitary adenoma (Cushing disease) versus ectopic ACTH — separated by high-dose dexamethasone suppression, which a pituitary adenoma still partly obeys and an ectopic tumor ignores |
Worked decision table · Gonadal axis (measure testosterone or estradiol + LH and FSH)
| Sex steroid | LH / FSH | Interpretation | Typical cause |
|---|---|---|---|
| Low | High | Primary (hypergonadotropic) hypogonadism — gonad failed | Menopause; Turner or Klinefelter syndrome; chemotherapy; orchitis; premature ovarian insufficiency |
| Low | Low or normal | Secondary (hypogonadotropic) hypogonadism — the axis above is silent | Pituitary tumor; hyperprolactinemia; anorexia or the athlete triad; Kallmann syndrome; opioids |
| Normal | FSH high, LH normal | Isolated seminiferous tubule damage | Loss of inhibin B with intact Leydig cells |
| High estradiol | Low LH/FSH | Exogenous estrogen or an estrogen-secreting tumor | Feedback suppression of the pituitary |
Check your diagnostic logic
- A 52-year-old woman has fatigue and cold intolerance. TSH is 24 mIU/L; free T₄ is low. Where is the lesion, and how do you know?
- A different patient has the same symptoms. TSH is 0.4 mIU/L (low-normal); free T₄ is low. Where is the lesion now, and what else should you check?
- Why can a random morning cortisol of 9 µg/dL be normal in one patient and diagnostic of disease in another?
Show answers
- Primary hypothyroidism — the thyroid gland itself. Feedback is intact: the pituitary detects low T₄ and correctly raises TSH. Effector and tropic hormones move in opposite directions, which is the signature of a Tier 3 lesion.
- Central hypothyroidism — a Tier 1 or Tier 2 lesion. Free T₄ is low, so the pituitary should be raising TSH; a "normal" TSH in the face of low free T₄ is inappropriately low and therefore abnormal. Check the rest of the anterior pituitary — ACTH/cortisol, LH/FSH, prolactin, IGF-1 — because pituitary lesions rarely take out one axis alone, and check cortisol first, since replacing thyroid hormone in an undiagnosed cortisol-deficient patient can precipitate adrenal crisis by raising metabolic clearance of what little cortisol they have.
- Because cortisol has a strong circadian rhythm. The same value that is appropriately near peak at 08:00 would be inappropriately high at midnight, when cortisol should be at its nadir. Loss of the diurnal rhythm is often the earliest sign of Cushing syndrome, which is why late-night salivary cortisol is a screening test and a single daytime draw is not.
F.6 Second-messenger systems by hormone class
Water-soluble hormones cannot enter the cell, so every one of them works by converting an extracellular binding event into an intracellular chemical signal. There are only a handful of mechanisms, and knowing which one a hormone uses predicts both its speed and its drug interactions.
| Pathway | Receptor type | Messenger and effector | Hormones that use it |
|---|---|---|---|
| Gs → adenylate cyclase | G-protein-coupled | cAMP → protein kinase A | Glucagon, ACTH, TSH, LH, FSH, hCG, PTH, calcitonin, ADH at V₂, CRH, GHRH, secretin, β-adrenergic effects of epinephrine |
| Gi → adenylate cyclase inhibited | G-protein-coupled | Falling cAMP | Somatostatin, dopamine at D₂ (prolactin inhibition), α₂-adrenergic |
| Gq → phospholipase C | G-protein-coupled | IP₃ → Ca²⁺ release from smooth ER; DAG → protein kinase C | TRH, GnRH, oxytocin, ADH at V₁, angiotensin II, gastrin, CCK, α₁-adrenergic effects |
| Receptor tyrosine kinase | Single-pass, intrinsic kinase | Autophosphorylation → IRS proteins → PI3K/Akt and MAPK | Insulin, IGF-1, most growth factors |
| JAK–STAT | Cytokine receptor, associated kinase | JAK phosphorylates STAT, which enters the nucleus directly | GH, prolactin, leptin, erythropoietin |
| Guanylyl cyclase | Membrane receptor with intrinsic cyclase (or soluble, for NO) | cGMP → protein kinase G | ANP, BNP; nitric oxide acting on vascular smooth muscle |
| Intracellular receptor | Cytoplasmic or nuclear; a transcription factor | Hormone–receptor complex binds a hormone response element on DNA | All steroids, thyroid hormone, calcitriol, retinoic acid |
Two patterns are worth extracting. First, amplification is a property of the cascade, not the hormone: one molecule of glucagon can, through Gs, adenylate cyclase, cAMP, and PKA, liberate on the order of 10⁶ to 10⁸ glucose molecules from hepatic glycogen. That is why picomolar hormone concentrations produce millimolar metabolic effects. Second, the pathway predicts the latency: G-protein and kinase cascades act in seconds because they modify proteins that already exist, whereas intracellular receptors act in 30 minutes to days because they must build proteins that do not.
Check Your Understanding F.6
- A drug blocks the conversion of ATP to cAMP. Predict which of the following hormones lose most of their effect: glucagon, cortisol, angiotensin II, PTH, aldosterone.
- Why does thyroid hormone take days to change a patient's metabolic rate, while epinephrine changes heart rate in one beat?
Show answers
- Glucagon and PTH — both signal through Gs and cAMP. Angiotensin II would be largely spared because it uses Gq, IP₃, and calcium. Cortisol and aldosterone would be entirely unaffected; they are steroids acting on intracellular receptors and never touch a second messenger at all.
- Because thyroid hormone works by changing gene transcription — it must produce new mRNA, new protein (including large numbers of Na⁺/K⁺-ATPase pumps and mitochondrial enzymes), and then wait for those proteins to accumulate. Epinephrine works by phosphorylating channels and proteins that are already sitting in the membrane of a pacemaker cell. Building takes days; switching takes milliseconds.
See also: Appendix B · Normal Laboratory Reference Values for reference intervals on the hormone assays named here, Appendix H · Units, Measures, and Physiological Constants for the unit conversions, and Chapter 16 · The Endocrine System for the mechanisms these tables compress.